An open-label, randomized, single intravenous dosing study to investigate the effect of fixed dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)

Walimbwa, Stephen IanKaboggoza, Julian PaulWaitt, CatrionaByakika-Kibwika, PaulineD'Avolio, AntonioLamorde, Mohammed2022-01-122022-01-122021Walimbwa, S. I., Kaboggoza, J. P., Waitt, C., Byakika-Kibwika, P., D'Avolio, A., & Lamorde, M. (2021). An open-label, randomized, single intravenous dosing study to investigate the effect of fixed dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR). https://orcid.org/0000-0002-3825-3260https://orcid.org/0000-0002-3825-3260https://nru.uncst.go.ug/xmlui/handle/123456789/1200Remdesivir is a novel broad-spectrum antiviral therapeutic with activity against several viruses that cause emerging infectious diseases. The purpose of this study is to explore how commonly utilized antiretroviral therapy (tenofovir disoproxil fumarate /lamivudine [TDF/3TC] and atazanavir/ritonavir [ATV/r]) influence plasma and intracellular concentrations of remdesivir.enRemdesivirCOVID-19EbolaHIVAtazanavirRitonavirTenofovirLamivudineDrug-drug interactionsAn open-label, randomized, single intravenous dosing study to investigate the effect of fixed dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)Article